Balyasny Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Balyasny Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-182,100	Closed	-$4.19M	–	3416
2025 Q4	$4.19M	Sell	182,100 -127,900	-41%	-$4.21M	0.01%	1492
2025 Q3	$9.32M	Buy	310,000 +125,000	+68%	+$3.75M	0.01%	1089
2025 Q2	$6.73M	Sell	185,000 -165,000	-47%	-$5.95M	0.01%	1147
2025 Q1	$12.7M	Buy	350,000 +250,000	+250%	+$10.4M	0.02%	787
2024 Q4	$4.21M	Buy	+100,000	New	+$4.96M	0.01%	1362
2022 Q4	–	Sell	-10,000	Closed	-$414K	–	3151
2022 Q3	$414K	Buy	+10,000	New	+$514K	﹤0.01%	2090

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Balyasny Asset Management's RARE Position: Q1 2026 in Review

Balyasny Asset Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 26% in Q1 2026, selling an estimated $3.06M and leaving 384,364 shares worth $8.05M. The position accounts for 0.01% of the portfolio, ranked #1135.

Balyasny Asset Management first reported a position in RARE in Q2 2015 and has held it in 21 quarters since. The position peaked at $12M in Q4 2025. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Balyasny Asset Management held 384,364 shares of Ultragenyx Pharmaceutical worth $8.05M as of Q1 2026.
Balyasny Asset Management sold 135,690 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.06M.
Ultragenyx Pharmaceutical made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1135 holding.
Balyasny Asset Management first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and has held it in 21 quarters since.
Balyasny Asset Management's Ultragenyx Pharmaceutical position peaked at $12M in Q4 2025.
296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.